MassChallenge

Selmod provides development of innovative small molecule therapies for the treatment of life-threatening invasive fungal infections.

Vaccine Systems expedites and simplifies vaccine preparation for caregivers and patients. Millions more people, particularly in the developing countries, can be immunized, saving tens of thousands of labor years through worldwide vaccination campaigns. Vaccine Systems creates equipment to help with this, resulting in increased access to vaccines, simplified preparation, and an essential margin of safety for those prepared at the point of care. At the same time, we reduce vaccine waste – which the WHO claims varies from 30% to 70% – and suboptimal vaccine re-allocation.

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

NurLabs develops label-free and reagent-free diagnostics to detect cancer early when it is most treatable.

Lepidext specializes in managing populations of Lepidoptera pests through the development of species-specific bio-pesticides. Founded in 2015 by Angelika Fath-Goodin and Bruce Webb in Lexington, Kentucky, the company aims to enhance crop security and promote agricultural prosperity. By leveraging a deep understanding of insect biology alongside farmers' expertise, Lepidext provides safe and effective pest control solutions that reduce reliance on genetically modified plants and chemical pesticides. Their technology specifically targets the corn earworm and other harmful insects, offering an innovative approach to pest management that is user-friendly and environmentally responsible.

Stemloop is a biotechnology company founded in 2019 and based in Evanston, Illinois. It focuses on developing cell-free biosensing products aimed at revolutionizing chemical and molecular testing. By utilizing genetically encoded sensing and response mechanisms, Stemloop creates simple and cost-effective solutions for the accurate and scalable detection of various chemicals. This innovation enables medical professionals to deliver better and faster test results while reducing costs, thereby enhancing the overall efficiency of testing processes in healthcare and related fields.

BioSense8 develops biosensors for use in human and animal healthcare, and environmental wellness. The company was founded in 2020 and is headquartered in Boston, Massachusetts.

Leucine Rich Bio is India's first and only Microbiome focused Genomics Based company. While, genomic approaches have gained huge clinical importance allowing us to align towards precision medicine, important uncertainties remain unanswered. The human microbiome, largely recognized as the "Second Genome", while rooted in the principles of genomics, have gained tremendous steam over the past few years. There is a heightened interest among researchers, clinicians and direct consumers in understanding the effects of the microbiome on health and wellness.

BioEclosion seeks to enhance user-friendly quantitative diagnostics to new molecular biomarkers for fast identification of emerging diseases that affect global health. The company started its activity with several patents, the most important being Celifast: a non-invasive approach for the detection of celiac disease. Addressing point of care attention of patients, the core technology has been successfully validated and the team is currently working on further development for commercialization.

Microbe Plus specializes in the development of innovative microbiological bio-products aimed at enhancing plant growth and protection. The company manufactures multi-strain probiotics for plants, which are formulated to safeguard crops against a wide range of pathogens, including diseases and pests. By utilizing carefully selected beneficial bacteria, Microbe Plus seeks to increase crop yields while minimizing the need for synthetic pesticides. Their mission is to create efficient and cost-effective solutions that support the health of various plants, including crops, orchards, flowers, and ornamental species, thereby contributing to sustainable agricultural practices.

Limula Biotech is a Swiss company specializing in the design and development of an automated system for manufacturing cell and gene therapies. The company has created a patented platform that enables the distributed production of genetically engineered cells directly at the patient's bedside, utilizing a patient's white blood cell sample. This fully closed bioreactor system minimizes human intervention during the manufacturing process while maintaining control over cell culture parameters. By facilitating on-site production in hospitals, Limula's technology aims to enhance the safety, accessibility, and efficiency of personalized gene therapies, ultimately reducing time, costs, and logistical challenges. Founded in 2018 and based in Lausanne, Switzerland, Limula Biotech is committed to revolutionizing the delivery of ex vivo gene-engineered cell therapies.

Octarine Bio is a biotechnology company based in Copenhagen, Denmark, founded in 2018. The company specializes in the research and development of cannabinoid and psilocybin derivatives using synthetic biology. By employing a biosynthetic platform, Octarine Bio aims to create a range of natural and novel cannabinoid and psilocybin-derived molecules that possess enhanced pharmacokinetic and therapeutic properties. These advancements are designed to support healthcare professionals in treating neurological and psychological disorders, ultimately improving the health and well-being of individuals.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

MIBIOMICS mission is to develop innovative, safe, and effective microbiome-based solutions to treat currently incurable skin diseases.

Computational Life Inc. develops a software that provides valuables flow and pressure dynamics throughout the body fluid system based on validated physical laws. The company provides a Digital Avatar Platform (DAP) that simulates the human and animal body through modern mathematical models. The company simulates arterial and venous systems, heart dynamics, microcirculation, pulmonary circulation, cerebrospinal fluid, and brain interstitial fluid. Computational Life Inc. was founded in 2018 and is based in Wilmington, Delaware.

Sano Chemicals is an early stage biotechnology company primarily focused on the development of novel anti-infectives for clinical and agricultural use. The word “Sano” is derived from the Latin word meaning health, thus, they are focused on the development of products that will promote their health and a healthy and sustainable environment. Sano Chemicals is focusing on the development of antifungal treatment options for fungal infections and antifungal bio-control methods for crops. Their goal is to innovate the anti-fungal industry. The antifungal occidiofungin is a completely unique antifungal compound discovered by researchers at Mississippi State University and Texas A&M University. Novel applications in occidiofungin's use are being developed through the innovative endeavors of their scientists. Products that cure fungal infections (nail, skin, and systemic), as well as products that promote a sustainable food supply by targeting fungal diseases in plants are being developed.

Gina Life is femtech company developing a platform of biomarkers strategy supported by AI for early detection in women’s health space.

Gina Life is femtech company developing a platform of biomarkers strategy supported by AI for early detection in women’s health space.

Developer of medical test kits designed to detect infections remotely. The company offers an on-the-spot saliva test kit using convenient sensitivity protein detection technology that identifies whether the user has an active infection or not, enabling people to understand and make informed decisions about their bodies and health.

Clara Biotech is focused on developing a platform technology for the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsies for early detection of various diseases, including cancer and Alzheimer's Disease. Unlike traditional methods that require lengthy ultra-centrifugation, Clara's platform can extract pure and viable exosomes from any biofluid source efficiently. This innovative process enhances the potential for precision medicine by enabling targeted drug delivery directly to specific cells. Additionally, Clara Biotech's technology supports the development of unique liquid biopsy assays, improving the accuracy of disease detection and addressing challenges faced by biopharma companies in the medical field. Overall, Clara Biotech aims to advance research into clinical applications, bridging the gap between laboratory findings and patient care through its exosome-based solutions.

Mushlabs GmbH is a biotechnology company based in Berlin, Germany, that specializes in producing mushroom mycelium as a raw ingredient for meat alternatives. Founded in 2018, the company employs a fermentation platform that harnesses the potential of fungi to create nutritious and sustainable food options. By focusing on the natural processes of fermentation, Mushlabs develops healthier and tastier products with minimal ingredients, catering to both meat-eaters and vegetarians. The company aims to transform food consumption by offering solutions that benefit consumers' health while also being environmentally friendly.

Developer of molecular technology intended to discover and deliver beneficial bacteria. The company's technology facilitates the production of next-generation probiotics, enabling clients to improve the wellness of humans and animals.

Mantle Biotech engineers binding proteins that can accurately identify disease biomarkers in patient samples, using directed evolution to modify heat-stable proteins produced by microbes. It allows the company to develop new diagnostic capabilities, producing high-quality binding proteins that are more stable and affordable than traditional reagents. This reagents can be adapted to a range of diseases and test formats, allowing the team to identify pain points throughout the broader diagnostic industry. Mantle Biotech was founded on 2019 and is headquartered in Cambridge, Massachusetts.

InvivoSciences specializes in phenotypic compound screening services that enhance drug discovery and repositioning. The company employs an innovative approach that combines tissue engineering technology with assay automation and sample miniaturization, facilitating rapid and cost-effective therapeutic discovery. Its mission focuses on developing engineered tissue-based assays that closely replicate the functions of living organisms, including humans and animals. By integrating patient-derived and gene-edited human samples, InvivoSciences aims to personalize the drug development process. The company utilizes advanced techniques in cell and tissue handling, tissue phenotyping assays, and computational biology, including artificial intelligence, to assist clinicians in swiftly identifying the safety and efficacy of treatments tailored to specific patient groups, thereby optimizing the preclinical phase before embarking on costly clinical trials.

MIBIOMICS mission is to develop innovative, safe, and effective microbiome-based solutions to treat currently incurable skin diseases.

CellSpring is a biotechnology company based in Zurich, Switzerland, focused on enhancing cell-based in vitro studies through innovative technology. Its flagship platform, 3D Bloom, allows for the rapid creation of biomimetic microtissues that are independent of cell type. This platform significantly improves upon traditional 3D cell culture methods by offering faster fabrication, greater reliability, and enhanced versatility. The microtissues developed using 3D Bloom are designed to serve various biological functions, including aiding clinicians in the early diagnosis of cancer. Through its advancements, CellSpring aims to facilitate fundamental improvements in the field of biotechnology and medical research.

SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB).

Operator of an environmental testing biotechnology company intended to ensure the safety of each chemical studied to protect human and environmental health. The company focuses on the development of technologies to analyze chemicals such as pesticides and consumer goods for bio-accumulation potential and utilizing in vitro technology to test for bioaccumulation to reduce both cost and experimentation time, enabling customers to deliver the quality service to ensure human and environmental health protection.

Fluent BioSciences is a privately funded life science company focused on developing high-sensitivity molecular analytical products. Utilizing proprietary instrument-free micro-self-assembly technology, the company enables the analysis of extremely low molecular and cellular sample inputs. Its platform facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions, allowing for sensitive and unbiased preparation of proteins and nucleic acids for sequencing applications. This innovative approach provides researchers in the biotechnology sector with enhanced capabilities for single-cell analysis, broadening their access to advanced analytical techniques.

Operator of a medical laboratory intended to provide various diagnostics tests to patients. The company offers tests based on the analysis of DNA in saliva for the evaluation of genetic risk to common diseases, prediction of response to commonly used drugs, and diagnosis of genetic diseases, enabling patients with personalized diagnosis and helping them avoid adverse drug effects and promote healthier lifestyles.

Scailyte AG is a Swiss company specializing in artificial intelligence-based software solutions for biomedical research and precision diagnostics. Founded in 2017 and located in Sursee, Scailyte has developed a data-driven biomarker discovery platform that focuses on the analysis of single-cell data. This platform enables the identification of a new class of biomarkers based on the molecular profiles of disease-associated cells, providing a novel approach to biomarker discovery that is closely aligned with disease biology. By enhancing the analysis of complex single-cell data, Scailyte's solutions aim to improve the efficiency and effectiveness of pharmaceutical discovery and patient stratification, ultimately reducing data analysis time and costs while delivering valuable insights for healthcare providers.

Scintia focuses on enhancing education and research in synthetic biology by providing innovative solutions designed to overcome barriers in biotechnology development. The company manufactures laboratory equipment and educational kits that facilitate hands-on learning experiences in genetic engineering. These kits include all necessary materials for conducting laboratory experiments, accompanied by comprehensive teaching guides for educators and students. By simplifying the educational process, Scintia enables users to engage in practical biological reactions, fostering a deeper understanding of synthetic biology concepts.

Developer of biological technology designed to increase the productivity of crops. The company creates organic products with the aim of optimizing the absorption of nutrients by plants without causing damage to the earth by revitalizing the root ecosystem and promoting synergy between the microorganisms, enabling clients to potentiate the crop yields.

LIfT BioSciences is a biotechnology start-up based in London, founded in 2016, that focuses on developing innovative immuno-oncology cell therapies for solid tumors. The company employs a unique platform centered on CAR neutrophil cell therapy, which aims to address the limitations of existing treatments by directly and indirectly attacking tumors. LIfT BioSciences specializes in creating immunomodulatory alpha neutrophils (IMANs) that enhance the tumor microenvironment, mobilizing the immune system to effectively target and destroy cancer cells. Their approach utilizes stem cells, proprietary enhancement media, and genetic engineering to produce CAR-IMAN cells, potentially offering patients significantly improved cancer-fighting capabilities. The company's ultimate goal is to establish a Cell Bank that harnesses Leukocyte Infusion Therapy to develop life-saving treatments for cancer patients.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes Caenorhabditis elegans, a type of microscopic worm, for the assessment of substances in pharmaceutical, chemical, and cosmetic industries. This technology, known as "Organism-on-Chip," integrates in vivo testing with a fully automated in vitro platform for handling, culturing, and analyzing these organisms. Nagi Bioscience's solutions facilitate toxicity testing, drug discovery, and anthelmintic testing, allowing clients to gain insights into the complete biological responses that can only be observed at the organism level. This approach aims to transform traditional methods of evaluating the toxic or beneficial effects of various substances.

Kernal Biologics, Inc. specializes in the design and development of mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company utilizes its mRNA platform to assist researchers and organizations in creating vaccines and therapeutics. Kernal's innovative therapies instruct specific cells to produce their own therapeutic agents, thereby enhancing treatment efficacy. The company has garnered recognition for its work, receiving multiple awards from notable institutions, including Amgen and NASA. With a foundation rooted in research from MIT and Harvard, the team at Kernal Biologics possesses extensive expertise in the mRNA field, building on their prior successes in the biotechnology sector.

LabSuit is an online lab management platform that helps life science researchers in managing their labs. LabSuit helps academic and industrial research labs to manage inventory, build lab catalogs, track orders, and synchronize essential lab activities between lab members. LabSuit was founded by Alexander Domeshek.

At Halo Life Science their aim is to Elevate Human Potential. After 3 years of research and development they are pleased to announce their initial, patent(s) pending product Naturalin™ - a phytonutrient that puts health and wellness into everything you eat and drink. Naturalin will also come in nutritional supplement forms. Validated safe, functional, and effective by researchers at the Dell Pediatric Research Institute at The University of Texas at Austin. Their mission is to deliver safe, effective, simple, affordable, accessible food and nutritional supplement products to everyone, everywhere.

Living A Book Inc. develops Pathbooks, an interactive book reading application that offers books in English and Spanish. Its application allows users to make decisions, change the story, and the end of the book. The company's application also allows book publishers to submit books on the platform for publishing. It also offers plans for the schools. The company serves e-books, mobile games, and physical books industries. Living A Book Inc. was founded in 2018 and is based in Redwood City, California.

Bezoar Laboratories focuses on enhancing health for humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products specifically designed to alleviate gastrointestinal issues, including bloating, constipation, and diarrhea. Their offerings are formulated to be free of gluten and dairy, and they maintain a low acidity level to ensure safety and effectiveness for consumers. By addressing these common health concerns, Bezoar Laboratories aims to improve overall well-being and promote healthier living.

Cellino Biotech, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in intracellular delivery lasers and nanotechnology specifically for gene editing applications. The company has developed an AI-guided laser editing platform that automates the generation of personalized, autologous cell therapies, significantly reducing the development time of engineered cells from years to weeks. By integrating advanced tools from optics, biology, and computation, Cellino makes stem cell differentiation a digital process, allowing healthcare providers to efficiently produce functionally mature cells at scale. This innovative approach aims to enhance the accessibility of life-saving medicines for patients.

ChemAlive SA develops and operates an online computational chemistry platform that delivers analytics for chemical sectors through its managed cloud computing, automation algorithms, and database. Its platform allows automatic calculation of quantum data for molecular properties and synthetic reactions available to chemists from 2D chemical syntax towards the silico prediction of chemical processes. The company’s automation, big data, and cloud-computing services enable results with methodologies useful to experts and non-experts in academic research, pharmaceuticals, fine chemicals, and contract research/manufacturing organizations. ChemAlive SA was founded in 2014 and is based in Lausanne, Switzerland.

Reminisciences develops a symbiotic treatment and a companion diagnostic for Alzheimer's disease through targeting the gut microbiome. Reminisciences exploits the crucial role of gut microbiota in human physiology and more specifically as we have discovered in Alzheimer's disease. There is no effective treatment for Alzheimer, despite 51 million patients in need. Our company develops 2 products: CerebralX, a symbiotic therapeutic treatment to restore altered gut microbiota and stop or delay Alzheimer's disease, and ReminiTest, a diagnostic based upon microbiota profiling.

ScienceMatters allows scientists to share their observations. ScienceMatters offers a platform with rich text editing and a modern interface to submit, edit, review, and publish observations.

Xsensio develops the unique Lab-on-Skin™​ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way. The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.

SUN bioscience SA is a bioengineering company based in Epalinges, Switzerland, founded in 2016. The company specializes in developing drug culture platforms that facilitate personalized medicine through the creation of patient-specific organoids, which are miniature 3D tissues derived from stem cells. Its flagship product, Gri3D, employs a proprietary high-throughput microwell array technology to produce these organoids, enabling reproducible image-based phenotypic screenings. By utilizing these organoids, SUN bioscience aims to enhance drug testing and the generation of safe, transplantable tissues, addressing current limitations in organoid culture related to scalability and automation. This innovative approach allows for early assessment of pharmaceutical efficacy and toxicity, paving the way for a new paradigm in drug discovery that moves beyond traditional animal or human testing.

SimplicityBio is a Swiss company founded in 2013 that focuses on biomarker discovery within the molecular diagnostics market. Utilizing an artificial intelligence-based platform, the company analyzes biological, clinical, and digital data streams to generate insights that facilitate the development process from target identification through pre-clinical and clinical phases. Its technology employs algorithms to explore biomarker signatures and identifies models based on user-defined criteria. SimplicityBio offers a range of services, including biomarker discovery and ranking, signature creation, and enhancement of existing signatures. The company also develops scientific innovations and intellectual property for its clients, positioning itself as a leader in the biomarker discovery sector. As of 2019, SimplicityBio operates as a subsidiary of Precision for Medicine, Inc.

Inq-ITS (www.inqits.com) are standards-aligned virtual labs for grades 5-10 science. They improve students' competency at science inquiry practices, and cut teachers' grading time by automatically scoring themselves. They want to help EVERY student learn science inquiry practices and critical thinking, and help empower EVERY educator to exceed new science standards. To be successful in the 21st Century, students need their education to go beyond rote memorization.The virtual science labs we create aim to help students to master the inquiry and critical thinking skills that will help them succeed in the classroom and beyond.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Every day too many LifeStories are being taken to the grave, lost forever. As the senior population explodes, there’s a yearning to rescue these priceless stories. But it's hard to write an entire life-and a writer is costly. Using our digital platform LJB will empower seniors everywhere to share the story of their lives with a LifeStory system that's easy, fun and affordable. When done, they’ll hit “Print” and we'll do the rest, creating a beautiful book, a lasting legacy for their loved ones.

DLS is creating new drugs to treat metabolic and cardiovascular diseases by mimicking favorable genotypes/phenotypes in nature. Some people are thinner than others, and DLS has identified a mutation in humans that causes thinness. The mutation in the target protein causes loss-of-function leading to the wasting of energy in the body and results in thinness. DLS is in the process of creating a small molecule inhibitor to the target protein that will similarly cause an inefficient metabolism and lead to thinness regardless of the cause of obesity. Following nature's example provides a safer path to curing obesity.

LambdaVision, Incorporated is focused on developing a protein-based artificial retina aimed at restoring vision for individuals affected by advanced retinal degenerative diseases, such as retinitis pigmentosa and age-related macular degeneration. Founded in 2009 and located in Farmington, Connecticut, the company is working to commercialize its retinal implant technology, which employs a light-activated protein known as bacteriorhodopsin. This innovative approach targets the stimulation of retinas in patients who have experienced significant sight loss, with the goal of enhancing their quality of life. Through its advancements, LambdaVision seeks to address the needs of millions who suffer from these debilitating conditions.

SmartScope is dedicated to improving early-stage malaria diagnosis through innovative technology. With malaria claiming over 400,000 lives annually, predominantly among children under five, the need for efficient diagnostic solutions is critical. The company has developed a smartphone-connected microscope adapter and a mobile application that leverages deep learning algorithms to facilitate rapid diagnosis of malaria. This platform allows medical staff, as well as individuals with minimal training, to conduct offline diagnoses quickly and effectively, significantly enhancing the speed and accessibility of malaria detection. By addressing the shortage of medical experts available for diagnosis, SmartScope aims to make a meaningful impact in the fight against this life-threatening disease.

Cellphmed is a bioinformatic platform enabling the discovery and early development of novel diagnostic biomarkers.

ScienceMatters allows scientists to share their observations. ScienceMatters offers a platform with rich text editing and a modern interface to submit, edit, review, and publish observations.

Gene sequencing and CRISPR/Cas9 technologies have enabled affordable genome mapping and editing with unprecedented precision; however, the bottleneck in understanding human disease mechanisms and bringing breakthrough therapies to patients faster now lies in the manual experimentation to introduce these new vectors into model organisms. HIVE Biosystems' rapid, self-driving instruments perform large-scale genetic modification and deep phenotyping of model organisms with deep learning algorithms.

TFC BioSciences specializes in the development and manufacture of liposome-based fluorescence detection systems known as Fluorosomes®. These innovative tools are designed to enhance drug discovery processes by measuring passive drug diffusion through membrane bilayers and characterizing interactions between P-glycoprotein and various drugs. By leveraging their Fluorosome® platform, TFC BioSciences aims to provide healthcare professionals with advanced research tools that prioritize performance, user-friendliness, and efficiency, thereby facilitating more effective ADMET studies in drug development. The company is committed to continuously expanding its technology to support the evolving needs of the pharmaceutical industry.

We live in a DNA society. DNA science can improve crops, solve crimes, and help inform medical treatments. Yet most of us have no firsthand experience with DNA technologies because they are complex and expensive. Amplyus’ mission is to give everyone access to DNA experimentation. Their miniPCR platform enables DNA analysis at a fraction of the cost and through a simple and educational interface. miniPCR puts DNA technology in the hands of students, enthusiasts, and more researchers.

Eulysis UK Limited is a device development company dedicated to enhancing the storage and delivery of pharmaceutical products. The company has introduced a revolutionary product known as the Single Vial System, which employs an innovative manufacturing process. This system enables the combination of a lyophilized active ingredient and its diluent for reconstitution within a single container. Traditionally, pharmaceutical products like vaccines and antibiotics have been stored and delivered in two separate containers, leading to inefficiencies and heightened risks such as contamination and increased raw material usage. By consolidating the components into one vial, Eulysis aims to streamline production, reduce transportation and storage costs, and minimize potential safety concerns.

SQZ Biotechnologies Company is a clinical-stage biotechnology firm based in Watertown, Massachusetts, focused on developing innovative cell therapies for cancer and other serious diseases. Its primary product candidate, SQZ-PBMC-HPV, is currently undergoing Phase I clinical trials as both a standalone treatment and in combination with other immuno-oncology agents for HPV16+ advanced or metastatic solid tumors. The company utilizes its proprietary CellSqueeze technology to deliver various materials into patient cells, aiming to engineer the immune system for both activation and suppression. Additionally, SQZ Biotech is advancing multiple platforms, including SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers, to address diverse clinical challenges. Established in 2013, the company is dedicated to transforming cell therapies through internal research and strategic partnerships.

Volvox Biologic is a biotechnology company focused on developing innovative solutions in the life sciences sector. The company is dedicated to advancing its research and product offerings through the guidance of a network of experienced mentors and advisors. By leveraging this expertise, Volvox aims to address critical challenges in the industry and enhance the quality of life through its biotechnological advancements. The company is committed to fostering collaboration and knowledge-sharing to drive its mission forward.

Nanoly Bioscience, Inc. develops polymers that enable temperature-sensitive molecules to survive without refrigeration. It develops polymers that are blended with protein-based temperature-sensitive molecules, such as enzymes, vaccines, and others to enable them to survive without refrigeration while transportation. Nanoly Bioscience, Inc. was incorporated in 2012 and is headquartered in Denver, Colorado.

Sextant Biosciences focuses on developing innovative cancer therapies utilizing its patented drug discovery technologies, which originated at MIT. The company aims to enhance cancer treatment by enabling tumors to trigger an immune response, rather than merely seeking to eliminate them. Sextant's pre-clinical drug discovery platform facilitates the identification of optimal drug combinations to prevent relapse and improve patient outcomes. Additionally, the platform provides experimental biology tools that assist biotech and pharmaceutical companies in making informed decisions regarding targeted drug treatments and the development of data-driven combination therapies and immuno-oncology drugs. Through these efforts, Sextant Biosciences seeks to bring more effective chemotherapies to market and significantly impact cancer care.

iSpecimen Inc. specializes in connecting life science researchers with essential human biospecimens, such as biofluids, tissues, and living cells, through its proprietary online platform, the iSpecimen Marketplace. This technology enables researchers to efficiently search for specimens and patient data across a network of hospitals, laboratories, biobanks, and blood centers worldwide. By facilitating access to these specimens, iSpecimen supports medical researchers, including those from biopharmaceutical companies, diagnostic firms, and academic institutions, in their scientific endeavors. Founded in 2009 and headquartered in Lexington, Massachusetts, the company operates on a global scale, primarily serving clients in the Americas, while also extending its reach to Europe, the Middle East, Africa, and the Asia Pacific region.

Factor Bioscience is building the future of regenerative medicine by targeting and repairing the molecular origins of disease. Factor Bioscience was established to explore new methods for controlling gene expression and cell fate. Their scientists developed the fastest, highest-efficiency method for reprogramming somatic cells to a pluripotent stem-cell state, a key invention now recognized by several patents. This technology, which enables the production of patient-specific cells for transplantation, has wide-ranging applications in personalized regenerative medicine.

Leiva Learning Strings provides a method for teaching students how to correlate musical notes to the cumbersome fingering positions of any stringed musical instrument by color-coding each note. The seven different colors are set to match the seven natural notes (A,B,C,D,E,F,G,) in music theory. With their patented Learning Strings, individuals can learn to play and read sheet music by matching colors making stringed instruments as fun and easy to learn as they are in the video game Guitar Hero.

Extend Biosciences Inc. is an emerging biotechnology company developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins. Peptides have been particularly challenging to bring to market because they are removed from circulation prior to administering therapeutic value. Their proprietary platform technology significantly improves the circulating half-life and bioavailability of peptides and proteins, enabling the scientific community to truly develop potent and specific drugs. Their mission is to revolutionize drug delivery and give patients a better quality of life.

ViThera Pharmaceuticals is an early stage biotech company located in the life-science cluster at One Kendall Square in Cambridge, MA. Our scientists harness the synthetic potential of bacteria to produce therapeutic molecules within the body to develop a revolutionary new treatment for Inflammatory Bowel Disease.Our research combines the natural benefits of probiotics with the power of synthetic biology to create game-changing, novel therapeutics for chronic diseases. EnLact strains are engineered lactic acid and probiotic bacteria which express beneficial proteins and modulate disease within the patient's body. Our lead program, VT301 uses EnLact technology to treat the inflammatory bowel disease, and is currently in pre-clinical development. Our close collaboration with prominent academic researchers developing the EnLact® in the United States and in Europe concept puts us at the cutting edge of biologic therapy. Strong proof of concept data supports the novel biology behind VT301 and we are currently conducting translational studies in human tissues in partnership with a large pharmaceutical company. The EnLact® strains in VT301 express human anti-inflammatory proteins that act locally on the inflamed mucosa and avoid systemic side effects.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Seeding Labs aims to enhance scientific research in developing countries by providing essential laboratory equipment, training, and networking opportunities for scientists. By focusing on areas such as healthcare improvement, climate-adaptive agriculture, and clean energy generation, Seeding Labs empowers researchers to address critical challenges related to health, food security, energy, environmental sustainability, and economic development. The organization has collaborated with scientists across 17 countries in Africa, Latin America, the Caribbean, and Asia, fostering a global network that promotes life-changing research and innovation. Through its initiatives, Seeding Labs is transforming the landscape of science and contributing to the advancement of knowledge and solutions in underserved regions.

Sextant Biosciences focuses on developing innovative cancer therapies utilizing its patented drug discovery technologies, which originated at MIT. The company aims to enhance cancer treatment by enabling tumors to trigger an immune response, rather than merely seeking to eliminate them. Sextant's pre-clinical drug discovery platform facilitates the identification of optimal drug combinations to prevent relapse and improve patient outcomes. Additionally, the platform provides experimental biology tools that assist biotech and pharmaceutical companies in making informed decisions regarding targeted drug treatments and the development of data-driven combination therapies and immuno-oncology drugs. Through these efforts, Sextant Biosciences seeks to bring more effective chemotherapies to market and significantly impact cancer care.